Clinical Trials Logo

Citation(s)

Phase I Study of MIDRIXNEO-LUNG, an Autologous Neoantigen-targeted Dendritic Cell Immunotherapy in Patients With Non-small Cell Lung Cancer

Details for clinical trial NCT04078269